Ignite Creation Date:
2024-05-06 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 2:24 PM
Study NCT ID:
NCT05234554
Status:
COMPLETED
Last Update Posted:
2024-04-18
First Post:
2022-02-01
Brief Title:
The INVIGORATE 2 Trial A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis
Sponsor:
Aldeyra Therapeutics Inc
Organization:
Aldeyra Therapeutics Inc
Study Overview
Official Title:
The INVIGORATE 2 Trial A Single-center Randomized Double-masked Crossover Design Vehicle-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Reproxalap Ophthalmic Solution 025 Compared to Vehicle in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber EEC
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The INVIGORATE 2 Trial A single-center randomized double-masked crossover design vehicle-controlled Phase 3 clinical trial to assess the efficacy and safety of reproxalap ophthalmic solution 025 compared to vehicle in subjects with seasonal allergic conjunctivitis using the environmental exposure chamber EEC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None